Study of a new treatment for moderate to severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with atopic dermatitis (eczema) for at least one year.
- Your eczema is moderate to severe (covers a lot of skin or is very hard to manage).
- You do not have another active skin condition (like psoriasis or a skin infection).
- You do not have an unstable medical condition that might make the study risky (for example, uncontrolled diabetes or high blood pressure).
- You do not have unstable asthma that requires frequent steroid treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
This trial tests an investigational cream called GX-03 for adults with moderate to severe eczema (atopic dermatitis). Participants apply the cream to affected skin daily, and the study compares it to a placebo cream to see if it improves symptoms safely.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.